Microbio Group’s new drugs business more complete in 2015. Microbio Group Chairman, Mr. William Lu expressed that marketing plans and market presence are being strengthened for the new drugs, “Chemo Young” and “Herbiron” which have already received new drug licenses; The chronic diabetic foot ulceration (ON101) new drug by Oneness Biotech will be applying for USA FDA’s fast track designation with data from clinical trials; while Fountain Biopharma’s three new drugs under development is planning to initiate licensing plans in China.

Microbio Group’s nine new drugs continue to show R&D results, in addition to FDA-approved new drugs, “Chemo Young” and “Herbiron”, the adjuvant to colorectal cancer therapy (MB-6) and chronic diabetic foot ulceration treatment drug (ON101) are currently administering phase III clinical trials. While Fountain Biopharma’s two anti-allergy new drugs and one rheumatoid arthritis new drug, are in the early human clinical trial stage, and already favored by China’s pharmaceutical companies, and actively negotiating licensing cooperation.

This year, Microbio Group is actively expanding the market for the two new drugs Chemo Young and Herbiron. A comprehensive marketing campaign is expected in mid-year to strengthen Herbiron’s sales and promotions in pharmacies and drug stores.

Chemo Young is currently available in 26 large sized hospitals in Taiwan, with goal of 80 hospitals throughout the year, and aiming towards the RMB 34 million yuan (approx. USD 1.13 million) market for chemotherapy drugs in China. Chemo Young has applied for imported drug inspections and registration, and will expand the overseas marketing plans through agents in the future.

Oneness Biotech’s chronic diabetic foot ulceration (ON101) new drug has collected over one hundred effective domestic phase III clinical trial data, and expects to complete phase III clinical data in 2016, working towards becoming the third licensed new drug for Microbio Group. According to statistics, chronic diabetic foot ulcers cure rate is only 25%, therefore Oneness Biotech will apply for USA FDA’s fast track designation based on clinical trial data.

Fountain Biopharma owns three new drugs in the early stages of human clinical trials, and plans to implement an international strategy plan with proper distribution of R&D resources and foreign licensing.

In order to strengthen and prepare for the commercialization of Microbio and Oneness Biotech new drugs, Microbio Group has already made plans to invest over NTD 1 billion (approx. USD 33.3 million) in a new factory in Longtan District of Taoyuan County. On the other hand, Oneness Biotech has passed a resolution to build Nanjhou factory in Pingtung County with a budget of NTD 500 million (approx. USD 16.7 million), to cultivate antrodia cinnamomea and manufacture WH-1 plectranthus amboinicus cream (estimated annual production of 20 million). Construction of the Nanjhou factory is expected to be completed by the end of 2015.

Microbio Group is also actively expanding its affiliate Cotton Field’s organic sales channels. In 2014, Cotton Field’s annual turnover amounted to NTD 1.142 billion (approx. USD 38.07 million), a 17.7% growth, with goal of achieving 70 retail stores in Q1 of 2016. Microbio’s health supplements brand “Lee Herb” launches in Cotton Field’s retail stores in May this year, to fully integrate the Group’s marketing resources. In the area of stock holding, “Diamond BioFund” will continue to invest in biotech companies with market potential, with vision towards positive development of the biotechnology industry.